EXETER, , Feb. 22 — Children with Down’s did not improve their Action Points
Explain to interested patients that early for children with Down’s may not improve .

Note that antioxidant supplements and folinic acid be recommended for children with Down’s based on the available .
with the use of antioxidant vitamins, researchers here found.
and scores were no better among British children with Down’s given antioxidants or folinic acid (an active of folic acid) or both than among those who received neither, reported , , of Peninsula , and colleagues in .

Nor were biochemical measures of oxidative improved by the supplements in the randomized controlled .

and supplements marketed as holding substantial benefits for children with Down’s are commonly used in the and Europe.

However, “parents who choose to give supplements to their children need to weigh their hope of unproved benefits against potential adverse effects from high , prolonged ,” the researchers wrote.

The lack of from may not be surprising because Down’s identifies differences between fetuses with and without trisomy 21 as early as 10 weeks’ , commented , M.D., of ’s in -Trent, , in an accompanying .

“Until of any of expensive supplements is available, they be recommended,” he said.

delay in Down’s has been thought to result from oxidative neuronal , abnormal folate metabolism, or both, they said. The , though, for nutritional interventions to counteract these effects has been poor, particularly in younger children, who had been thought to be most likely to .

So the researchers undertook a well-designed study among 156 infants younger than seven months with Down’s but no severe cardiac defects or other serious long-term illness.

They randomized the children to a daily oral of antioxidants (selenium 10 μg, zinc 5 mg, A 0.9 mg, E 100 mg, and C 50 mg) or folinic acid (0.1 mg) or both, or placebo.

All were given as a powder to be mixed with food or drink and were increased in by 30% after a ’s first birthday.

After 18 months of follow-up, overall scores as measured on the Griffiths mental scales were similar between children given antioxidants and those who were not (mean 57.3 versus 56.1; adjusted mean 1.2 points, 95% −2.2 to 4.6).

Likewise, scores were similar for children randomized to folinic acid supplements or not (mean 57.6 versus 55.9; adjusted mean 1.7, 95% CI −1.7 to 5.1).

For after 18 months of follow-up, the number of words said or signed was similar for children given antioxidants versus ( of means 0.85, 95% CI 0.6 to 1.2) and for those given folinic acid versus ( of means 1.24, 95% CI 0.87 to 1.77).

Nor was there any in the age at which infants reached milestones in motor .

Age at sitting without support was not significantly improved with antioxidants (hazard 1.10, 95% 0.77 to 1.56) or folinic acid (HR 1.25, 95% CI 0.88 to 1.78).

Standing did not start significantly earlier with antioxidants (HR 1.25, 95% CI 0.88 to 1.78) or folinic acid (HR 1.14, 95% CI 0.76 to 1.71).

To see whether the supplements could be having a subclinical , the researchers looked at biomarkers of oxidative in samples obtained at age one and urine samples.

Activity of antioxidant enzymes — red superoxide dismutase and red glutathione peroxidase — was not detectably different between treatment groups. Urinary isoprostane concentrations, a marker of lipid perioxidation, were also similar across groups, “indicating that did not affect oxidative .”

The only short-term side in the study was an increase in vomiting among infants taking antioxidants (P=0.002), “but the side effects of higher preparations used over a long period are unknown.”

Doses used in the study were at least 100% of the recommended daily allowance for all the vitamins and folinic acid, but still were relatively low compared with commercially available preparations, they noted.

“We were reluctant to use higher doses, as data on the safety of high doses for young children are lacking and high C may in fact exhibit pro-oxidant properties,” and colleagues wrote.

The study was funded by the Down’s Association, Fondation Jérôme Lejeune, Down , and Szeben Peto . The work was done at GOSH/UCL Institute of , which received partial from the Department of ’s NIHR Biomedical Centers scheme.

reported having been paid to speak at conferences on for Down’s and receiving consulting fees from several manufacturers of analytical reagents.

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Related posts